A randomized single blind safety and efficacy study of TOL-463 vaginal GEL or insert in the treatment of vaginitis (BV and/or VVC)
Ended Awarded Last action
- Contract number
- HHSN27200008
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $998,596
Award facts
- Contract value 48% obligated
-
- $998,595.82 Current, with exercised options
- $2,076,810.82 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Birmingham, AL 35294, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$330,258 | |
| Exercise an Option | $141,754 | |
| Supplemental Agreement for work within scope | $62,563 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $936,461 | |
| Original award | $188,076 |
About this award
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to the University of Alabama at Birmingham (UAB) for a randomized, single-blind safety and efficacy study of a vaginal gel or insert called TOL-463 in the treatment of vaginitis. The contract has a ceiling value of $2,076,810.82 and a completion date of November 30, 2017. There is no set-aside designation for this award.
As part of this contract, UAB has awarded subcontracts to Family Health International (FHI 360) to serve as the Operations Coordinating Center and develop the phase 2 clinical trial protocol, as well as to the University of Washington to conduct participant enrollment and oversee clinical research activities. This study aims to evaluate the efficacy of the TOL-463 product in treating bacterial vaginosis and/or vulvovaginal candidiasis. The project involves collaboration between the NIAID, the contract awardees, and other scientific and technical personnel.
Quick answers
Who was awarded contract HHSN27200008?
HHSN27200008 was awarded to University Of Alabama At Birmingham by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 8, 2015.
How much is contract HHSN27200008 worth?
The government has obligated $998,596 on HHSN27200008. Its potential value, with all options, is $2,076,811.
Is contract HHSN27200008 an order under another contract?
Yes. HHSN27200008 is a delivery order under HHSN272201300012I, an indefinite delivery contract.
Was contract HHSN27200008 competed?
The extent of competition for HHSN27200008 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award